Spots Global Cancer Trial Database for anaplastic astrocytoma
Every month we try and update this database with for anaplastic astrocytoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma | NCT00003470 | Anaplastic Astr... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | NCT02039778 | Glioblastoma Malignant Gliom... Brain Tumors Anaplastic Astr... | Stem Cell Radio... | 18 Years - 70 Years | Beth Israel Medical Center | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| Targeted Pediatric High-Grade Glioma Therapy | NCT05839379 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | 12 Months - 39 Years | Nationwide Children's Hospital | ||
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | NCT00041587 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | NCT00031083 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... Gliosarcoma | Interferon-beta | 18 Years - | Biogen | |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | NCT06108206 | Glioblastoma Anaplastic Astr... Astrocytoma Anaplastic Olig... | Adaptive Radiot... | 18 Years - | Columbia University | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients | NCT00876499 | Brain Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Radiotherapy for Malignant Astrocytomas in the Elderly | NCT00430911 | Primary Brain T... Anaplastic Astr... Glioblastoma Mu... | Radiotherapy | 70 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | NCT00539344 | Recurrent or Pr... | ANG1005 | 18 Years - | Angiochem Inc | |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | NCT00062504 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | Talampanel | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | NCT03072134 | Glioma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Mu... Astrocytoma, Gr... Astrocytoma, Gr... Brain Cancer | Neural stem cel... | 18 Years - | Northwestern University | |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | NCT04295759 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... DIPG High-grade Astr... CNS Primary Tum... | INCB7839 | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma | NCT03633552 | Glioblastoma Mu... Anaplastic Astr... | Temozolomide | 18 Years - 70 Years | Mashhad University of Medical Sciences | |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | NCT01238237 | Glioblastoma Mu... ANAPLASTIC ASTR... GBM Anaplastic Astr... | Superselective ... | 18 Years - | Northwell Health | |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | NCT00024570 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Genetic Analysis of Brain Tumors | NCT00031538 | Glioma Glioblastoma Mu... Anaplastic Astr... Oligodendroglio... Astrocytoma | 1 Year - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | NCT00035373 | Glioblatoma Gliosarcoma Anaplastic Astr... Oligodendroglio... Anaplastic Olig... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | NCT00589875 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | CAN-2409 Valacyclovir Temozolomide Radiation thera... | 18 Years - | Candel Therapeutics, Inc. | |
| 3D Prediction of Patient-Specific Response | NCT03561207 | Advanced Cancer Ovarian Cancer Glioblastoma Mu... Anaplastic Astr... | EV3D Assay | 18 Years - | KIYATEC | |
| Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | NCT00024557 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... Malignant Astro... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Cellular Immunotherapy Study for Brain Cancer | NCT01144247 | Gliomas Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... Glioblastoma Mu... Malignant Menin... | alloreactive CT... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | NCT01082926 | Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor | therapeutic all... aldesleukin laboratory biom... positron emissi... | 18 Years - 70 Years | City of Hope Medical Center | |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | NCT01837862 | Pilomyxoid Astr... Pilocytic Astro... Glioma, Astrocy... Optic Nerve Gli... Pleomorphic Xan... Glioblastoma Mu... Anaplastic Astr... Gliosarcoma Diffuse Intrins... DIPG Low-grade Gliom... Brainstem Gliom... | Mebendazole Vincristine Carboplatin Temozolomide Bevacizumab Irinotecan | 1 Year - 21 Years | Northwell Health | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Loupe-Based Intraoperative Fluorescence Imaging | NCT04780009 | Glioblastoma Mu... Anaplastic Astr... | 18 Years - 90 Years | University of Kentucky | ||
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents | NCT01517776 | Gliomas | Cilengitide Temozolomide | 3 Years - 17 Years | Martin-Luther-Universität Halle-Wittenberg | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | NCT02885324 | Glioblastoma Mu... Anaplastic Astr... Malignant Brain... High Grade Glio... | Cabozantinib | 2 Years - 21 Years | Indiana University | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | NCT01095094 | Brain Tumor Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Brain Stem Glio... Giant Cell Glio... Glioblastoma Gliosarcoma Mixed Glioma | ritonavir lopinavir | 18 Years - | Case Comprehensive Cancer Center | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | NCT00968240 | Glioblastoma Mu... Anaplastic Astr... | Super-Selective... | 18 Years - | Northwell Health | |
| (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | NCT01281982 | Low Grade Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Oligoastrocytom... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | NCT00089427 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... | IL13-PE38QQR Surgery for pla... Radiation thera... Temozolomide wi... | 18 Years - | INSYS Therapeutics Inc | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | NCT02800486 | Glioblastoma Anaplastic Astr... Anaplastic Olig... Glioma Brain Neoplasm Brain Cancer Brain Tumor Brain Tumor, Re... Brain Neoplasm,... | Intra-arterial ... Intra-arterial ... Hypofractionate... | 18 Years - | Northwell Health | |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | NCT00064779 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | NCT02372409 | Glioma Pilocytic Astro... Anaplastic Astr... Glioblastoma Mixed Oligoastr... Mixed Glioma Oligodendroglio... Optic Glioma Astrocytoma | MRI-guided lase... Doxorubicin Etoposide Dynamic contras... Dynamic suscept... | 3 Years - 21 Years | Washington University School of Medicine | |
| Study of Ribociclib and Everolimus in HGG and DIPG | NCT05843253 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | Ribociclib Everolimus | 12 Months - 39 Years | Nationwide Children's Hospital | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | NCT00616005 | Glioblastoma | Temodar and Iri... | 18 Years - | Duke University | |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | NCT00539344 | Recurrent or Pr... | ANG1005 | 18 Years - | Angiochem Inc | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | NCT00114309 | Malignant Gliom... Glioblastoma Mu... GBM Anaplastic Astr... Oligo-Astrocyto... Gliosarcoma | 131-I-TM-601 131I-TM601 | 18 Years - | TransMolecular | |
| Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | NCT01151670 | Brain Neoplasms... Brain Neoplasms... Malignant Menin... Glioblastoma Mu... Anaplastic Astr... | pioglitazone Pioglitazone | 18 Years - | Wake Forest University Health Sciences | |
| Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas | NCT00610571 | Glioblastoma Gliosarcoma Anaplastic Astr... | Oral Topotecan ... | 18 Years - | Duke University | |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | NCT06333899 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Infant Type Hem... Glioblastoma Glioblastoma Mu... WHO Grade III G... WHO Grade IV Gl... Diffuse Midline... | Lorlatinib Lorlatinib with... Lorlatinib with... Lorlatinib post... | 1 Year - 21 Years | Nationwide Children's Hospital | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | NCT01808820 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | Dendritic Cell ... Tumor Lysate Imiquimod Leukapheresis | 13 Years - 99 Years | University of Miami | |
| Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma | NCT00003470 | Anaplastic Astr... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | NCT04047303 | Astrocytoma Glioblastoma | CC-90010 | 18 Years - | Celgene | |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | NCT00612651 | Gliosarcoma Glioblastoma Anaplastic Astr... | Temodar and SCH... | 18 Years - | Duke University | |
| Expanded Access to ANG1005 for Individual Patients | NCT02755987 | Anaplastic Astr... Anaplastic Olig... Breast Cancer W... Leptomeningeal ... | ANG1005 | 18 Years - | Angiochem Inc | |
| BIBF 1120 for Recurrent High-Grade Gliomas | NCT01380782 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | BIBF 1120 | 18 Years - | Dana-Farber Cancer Institute | |
| Expanded Access to ANG1005 for Individual Patients | NCT02755987 | Anaplastic Astr... Anaplastic Olig... Breast Cancer W... Leptomeningeal ... | ANG1005 | 18 Years - | Angiochem Inc | |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | NCT02644291 | Medulloblastoma Astrocytoma, Gr... Glioblastoma Anaplastic Astr... Brain Stem Neop... Oligodendroblas... Anaplastic Olig... Malignant Gliom... | Mebendazole | 1 Year - 21 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
